Amitraz and its metabolite N'-(2,4-dimethylphenyl)-N-methyl-formamidine (BTS-27271) were administered orally to white rats. Both compounds were rapidly metabolized and eliminated primarily via the urine. The cumulative percentage of the dose eliminated in the urine was 77.6 for amitraz and 88.7 for BTS-27271 by 96 hr posttreatment. Amitraz degradation products present in urine included BTS-27271, 2,4-dimethylformanilide, 2,4-dimethylaniline, 4-formamido-3-methylbenzoic acid, 4-amino-3-methylbenzoic acid, and several unknowns. BTS-27271 degradation products in rat urine were similar to those found with amitraz. Tissue residues generally were low (less than 25 ppb) with the exception of those in liver.